• Berndt U., Stanetty C., Wanek T. et al. (2008) Synthesis of a [18F]fluorobenzothiazole as potentioal amyloid imaging agent. J. Label. Compd. Radiopharm. 51, 137145.
  • Braak H. and Braak E. (1991) Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. (Berl.) 82, 239259.
  • Cai L., Innis R. B. and Pike V. W. (2007) Radioligand development for PET imaging of β-amyloid (Aβ)-current status. Curr. Med. Chem. 14, 1952.
  • Dubois B., Feldman H. H., Jacova C. et al. (2007) Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 6, 734746.
  • Duff K., Eckman C., Zehr C. et al. (1996) Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin. Nature 383, 710713.
  • Forsberg A., Engler H., Almkvist O., Blomquist G., Hagman G., Wall A., Ringheim A., Långström B. and Nordberg A. (2007) PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol. Aging 29, 14561465.
  • Henriksen G., Yousefi B. H., Drzega A. and Wester H.-J. (2007) Development and evaluation of compounds for imaging of β-amyloid plaque by means of positron emission tomography. Eur. J. Nucl. Med. Mol. Imaging 35(Suppl. 1), S75S81.
  • Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya S., Yang F. and Cole G. (1996) Correlative memory deficits, abeta elevation, and amyloid plaques in transgenic mice. Science 274(5284): 99102.
  • Ikonomovic M. D., Klunk W. E., Abrahamson E. E. et al. (2008) Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer’s disease. Brain 131(6), 16301645.
  • Klunk W. E., Wang Y., Huang G. F., Debnath M. L., Holt D. P. and Mathis C. A. (2001) Uncharged thioflavin-T derivates bind to amyloid-beta protein with high affinity and readily enter the brain. Life Sci. 69, 14711484.
  • Klunk W. E., Engler H., Nordberg A. et al. (2004) Imaging brain amyloid in Alzheimer’s disease with Pittsburgh compound-B. Ann. Neurol. 55, 306319.
  • Klunk W. E., Lopresti B. J., Ikonomovic M. D. et al. (2005) Binding of the positron emission tomography traces Pittsburgh compound-B reflects the amount of amyloid-β in Alzheimer’s disease brain but not in transgenic mouse brain. J. Neurosci. 25, 1059810606.
  • Kudo Y., Okamura N., Furumoto S., Tashiro M., Furukawa K., Maruyama M., Itoh M., Iwata R., Yanai K. and Arai H. (2007) 2-(2-[2-dimethylaminothiazol-5-yl]ethenyl)-6-2-[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer’s disease patients. J. Nucl. Med. 48, 553561.
  • Lansbury P. T. and Lashuel H. A. (2006) A century-old debate on protein aggregation and neurodegeneration enters the clinic Nature 443, 774779.
  • Lockhart A., Lamb J. R., Osredkar T., Sue L. I., Joyce J. N., Ye L., Libri V., Leppert D. and Beach T. G. (2007) PIB is a non-specific imaging marker of amyloid-beta (Aβ) peptide-related cerebral amyloidosis. Brain 130(Pt 10):26072615.
  • Mathis C. A., Lopresti B. J. and Klunk W. E. (2007a) Impact of amyloid imaging on drug development in Alzheimers’s disease. Nucl. Med. Biol. 34, 809822.
  • Mathis C. A., Lopresti B. J., Mason N., Price J. C., Flatt N., Bi W., Ziolko S., DeKosky S. and Klunk W. E. (2007b) Comparison of the amyloid imaging agents [18F]3′-F-PIB and [11C]PIB in Alzheimer’s diseas and control subjects. Meeting abstract. J. Nucl. Med. 48(Suppl. 2), 56.
  • Nilsson M. R. (2004) Techniques to study amyloid fibril formation in vitro. Methods 34, 151160.
  • Nordberg A. (2007) Amyloid imaging in Alzheimer’s disease. Curr. Opin. Neurol. 20, 398402.
  • Paxinos G. and Franklin K. B. J. (1997) The Mouse Brain in Stereotaxic Coordinates. Academic Press, San Diego, CA.
  • Pike K. E., Savage S., Villemange V. L., Ng S., Moss S. A., Maruff P., Mathis C. A., Klunk W. E., Masters C. L. and Rowe C. C. (2007) β-Amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer’s disease. Brain 130, 28372844.
  • Rowe C. C., Ackerman U., Browne W. et al. (2008) Imaging of amyloid β in Alzheimer’s disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Neurology 7(2), 129135.
  • Verhoeff N. P., Wilson A. A., Takeshita S., Trop L., Hussey D., Singh K., Kung H. F., Kung M. P. and Houle S. (2004) In vivo imaging of Alzheimer disease beta amyloid with [11C]SB-13 PET. Am. J. Geriatr. Psychiatry 12, 584595.
  • Ye L., Morgenstern J. L., Lamb J. R. and Lockhart A. (2006) Characterisation of the binding of amyloid imaging tracers to rodent Aβ fibrils and rodent-human co-polymers. BBRC 347, 669677.